Success Story: Advancing Cancer Biology Research: NIW Approval for a Taiwanese PhD Student Researcher
Client’s Testimonial:
“Again, thank you so much for your help that make my NIW petition get approved!”
On September 28th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Research Assistant in the Field of Cancer Biology (Approval Notice).
General Field: Cancer Biology
Position at the Time of Case Filing: Graduate Research Assistant
Country of Origin: Taiwan
State of Residence at the Time of Filing: Louisiana
Approval Notice Date: September 28th, 2026
Processing Time: 17 months, 25 days (Premium Processing Upgrade Requested)
Case Summary:
A recent EB-2 NIW approval was granted to a cancer biology PhD student researcher from Taiwan whose work focuses on studying factors within tumor environments that may affect chemotherapy response and cancer treatment efficacy.
The client’s proposed endeavor centered on the use of cancer models, molecular biology assays, and multi-omics analyses to better understand how tumor immune microenvironments may contribute to treatment resistance. North America Immigration Law Group (NAILG) structured the petition to emphasize the national importance of cancer biology research, particularly work that may help inform more effective treatment strategies and improve long-term patient outcomes.
The petition explained that the client’s research addresses an important challenge in cancer treatment: why some cancer cells survive chemotherapy and how the surrounding immune environment may contribute to that survival. Rather than presenting the work only as a laboratory-based study, NAILG framed the proposed endeavor as part of broader efforts to improve understanding of treatment resistance and support the development of more effective therapeutic strategies.
The client’s academic and professional record reflects strong preparation for this endeavor. Specifically:
- M.S. in microbiology
- 5 peer-reviewed journal articles, including 1 first-authored article, and 4 abstracts
- 169 citations across published work
At the time of filing, the client was conducting research at a U.S.-based academic institution, where the client continued work involving cancer biology, molecular immunology, chemotherapy response, and bioinformatic analysis. The petition connected this current research to the proposed endeavor by showing that the client’s ongoing work built directly on prior experience in cancer cell biology, tumor immune microenvironments, and molecular mechanisms related to treatment resistance.
Beyond publication metrics, the client’s research demonstrated measurable influence within cancer biology and related biomedical fields. The petition showed that 2 of the client’s papers ranked among the top 10% most-cited Molecular Biology and Genetics articles for their respective publication years, while another ranked among the top 20%. This helped place the citation record in context and demonstrated that the client’s work had attracted meaningful attention from other researchers.
NAILG also demonstrated the client’s significance by showing that independent researchers had relied on the client’s findings in later studies involving cancer treatment resistance, immune-related mechanisms, disease signaling pathways, and inflammation. These examples helped establish that the client’s work had practical value beyond publication and had contributed to broader research efforts aimed at understanding disease progression and improving therapeutic approaches.
The petition did not rely on any single metric. Instead, NAILG presented the client’s education, publication record, citation impact, current research role, and continued plans in the field as an integrated record showing that the client was well positioned to advance the proposed endeavor. This approach helped connect the client’s prior achievements to the future work described in the petition.
USCIS approved the I-140 National Interest Waiver petition on September 28th, 2026, after a premium processing upgrade was requested. This approval reflected the successful presentation of a structured evidentiary record highlighting the national importance of cancer biology research and the client’s sustained contributions to understanding chemotherapy response, tumor microenvironments, and related biomedical mechanisms.